Effect of drospirenone on apoptosis and anti-proliferation in ectopic endometrial stromal cells: an in vitro study

Status

Unknown

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20221129005

Enrollment

Registered

2022-11-29

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis Endometriosis Ectopic endometrial stromal cells Drospirenone Apoptosis

Interventions

Eutopic endometrial stromal cells without drospirenone treatment, Eutopic endometrial stromal cells with drospirenone treatment,Ectopic endometrial stromal cells without drospirenone treatment,Eutopic

No Intervention No treatment,Experimental Drug,No Intervention No treatment,Experimental Drug

EuSC control,EuSC drospirenone,EcSC control,EcSC drospirenone

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Women age 18-45 years Diagnosis of endometriotic cyst and undergoing ovarian cystectomy or SO or BSO No hormonal treatment in last 3 months

Exclusion criteria

Exclusion criteria: Gynecologic malignancy Failed endometrial sampling On medication with effect to endometrial cell proliferation

Design outcomes

Primary

Measure	Time frame
Anti-proliferation and apoptosis 24 hours Flow cytometry	—

Secondary

Measure	Time frame
Dose of drospirenone 24 hours Flow cytometry	—

Countries

Thailand

Contacts

Public ContactPawitra Suwannalert

Faculty of medicine, Siriraj hospital

pawitra.suwannalert@gmail.com0869290904

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026